Brought to you by 
Abbott Molecular to develop pharmacogenomic test for Tarceva
12 Mar 2008
Executive Summary
OSI Pharmaceuticals and its licensees Genentech and Roche have called on Abbott's molecular diagnostics division to develop a test to identify patients most likely to respond to the non-small cell lung cancer drug Tarceva (erlotinib).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott Molecular to develop pharmacogenomic test for Tarceva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice